Clinical trials: CXCR2 Expression
- Condition CXCR2 Expression
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Infections, Respiratory Syncytial Virus
Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression
This study is to determine danirixin (GSK1325756) concentrations required to inhibit neutrophil activation in blood obtained from Respiratory Syncytial Virus (RSV)-infected children <2 years and healthy adults.
- Trial name
- NCT02201303
- Testing
- Danirixin, CXCL1
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline